News
10-30-2015, 02:00 AM
Halozyme Therapeutics, Inc. today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics, Inc. and being developed by Pfizer Inc., using Halozyme's ENHANZE formulation.
More... (http://www.news-medical.net/news/20151030/Halozyme-Therapeutics-announces-initiation-of-rivipansel-Phase-1-clinical-trial.aspx)
More... (http://www.news-medical.net/news/20151030/Halozyme-Therapeutics-announces-initiation-of-rivipansel-Phase-1-clinical-trial.aspx)